49,259
edits
| (4 intermediate revisions by the same user not shown) | |||
| Line 39: | Line 39: | ||
In the clinical context, it is often referred to as '''non-small cell lung cancer'''; this ignores the fact that not all non-small cell lung cancer fits into the [[carcinoma]] category. | In the clinical context, it is often referred to as '''non-small cell lung cancer'''; this ignores the fact that not all non-small cell lung cancer fits into the [[carcinoma]] category. | ||
''Poorly differentiated carcinoma of the lung'' and ''poorly differentiated lung carcinoma'' redirect to this article. | ''Poorly differentiated carcinoma of the lung'', ''non-small cell carcinoma'' and ''poorly differentiated lung carcinoma'' redirect to this article. | ||
==General== | ==General== | ||
| Line 69: | Line 69: | ||
===Grading=== | ===Grading=== | ||
*NSCC-NOS, NSCC | *''NSCC-NOS'', ''NSCC favour adenocarcinoma'', ''NSCC favour SCC'' are grade 4. | ||
Note: | Note: | ||
| Line 89: | Line 89: | ||
Note: | Note: | ||
* | *If immunostains favour adenocarcinoma or squamous cell carcinoma, the case should be sign as ''favour adenocarcinoma'' or ''favour squamous cell carcinoma'', see ''Sloan-Kettering algorithm'' below and ''Sign out'' section. | ||
===Adenocarcinoma versus squamous carcinoma=== | ===Adenocarcinoma versus squamous carcinoma=== | ||
| Line 122: | Line 122: | ||
|- | |- | ||
| Non-small cell carcinoma, favour adenocarcinoma | | Non-small cell carcinoma, favour adenocarcinoma | ||
| TTF-1 or napsin +ve | | [[TTF-1]] or napsin +ve | ||
|- | |- | ||
| Non-small cell carcinoma, favour squamous cell carcinoma | | Non-small cell carcinoma, favour squamous cell carcinoma | ||
| p40 or p63 +ve | | [[p40]] or [[p63]] +ve | ||
|- | |- | ||
| Non-small cell carcinoma-not otherwise specified | | Non-small cell carcinoma-not otherwise specified | ||
edits